Kane Biotech Secures FDA Clearance for Antimicrobial Skin and Wound Cleanser
Event summary
- Kane Biotech received FDA 510(k) clearance for its revyve® Antimicrobial Skin and Wound Cleanser on February 17, 2026.
- The cleanser is intended for a broad range of acute and chronic dermal lesions, including pressure ulcers, diabetic foot ulcers, and minor cuts.
- Kane expanded its ISO 13485:2016 certification under the Medical Device Single Audit Program (MDSAP) to include distribution and wound cleansers.
- Manufacturing technology transfer and scale-up of the cleanser are planned for later in 2026, with sales activities to follow.
The big picture
Kane Biotech’s FDA clearance for its antimicrobial cleanser strengthens its wound care platform, addressing biofilms and antibiotic resistance. The expansion of its ISO 13485 certification aligns with the FDA’s new QMSR, demonstrating the company’s commitment to quality and compliance. This strategic move positions Kane Biotech to pursue regulatory approvals across multiple jurisdictions, potentially expanding its market reach and revenue streams.
What we're watching
- Regulatory Alignment
- Whether Kane Biotech can sustain its compliance with evolving regulatory expectations, particularly with the FDA’s new Quality Management System Regulation (QMSR).
- Market Penetration
- The pace at which Kane Biotech can scale up manufacturing and launch sales activities for the revyve® Antimicrobial Skin and Wound Cleanser.
- Competitive Positioning
- How the expanded revyve product line will position Kane Biotech against competitors in the wound care market.
Related topics